Cite
APA Citation
Seto, T., Nosaki, K., Shimokawa, M., Toyozawa, R., Sugawara, S., Hayashi, H., Murakami, H., Kato, T., Niho, S., Saka, H., Oki, M., Yoshioka, H., Okamoto, I., Daga, H., Azuma, K., Tanaka, H., Nishino, K., Tohnai, R., Yamamoto, N., & Nakagawa, K. (2022). phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). Journal for immunotherapy of cancer, 10(2), . http://access.bl.uk/ark:/81055/vdc_100150523910.0x000009